These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26940988)

  • 21. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.
    Hoare P; Remschmidt H; Medori R; Ettrich C; Rothenberger A; Santosh P; Schmit M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):305-9. PubMed ID: 16220214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway.
    Karlstad Ø; Furu K; Skurtveit S; Selmer R
    Eur Addict Res; 2014; 20(2):59-65. PubMed ID: 24080771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
    Maia CR; Matte BC; Ludwig HT; Rohde LA
    Eur Child Adolesc Psychiatry; 2008 Apr; 17(3):133-42. PubMed ID: 17846812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
    Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
    Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
    Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
    J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder.
    Baskin BM; Dwoskin LP; Kantak KM
    Pharmacol Biochem Behav; 2015 Apr; 131():51-6. PubMed ID: 25643872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of potential agonist-replacement therapies for stimulant dependence on inhibitory control in cocaine abusers.
    Vansickel AR; Fillmorex MT; Hays LR; Rush CR
    Am J Drug Alcohol Abuse; 2008; 34(3):293-305. PubMed ID: 18428072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users.
    Darredeau C; Barrett SP; Jardin B; Pihl RO
    Hum Psychopharmacol; 2007 Dec; 22(8):529-36. PubMed ID: 17910020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder.
    Somoza EC; Winhusen TM; Bridge TP; Rotrosen JP; Vanderburg DG; Harrer JM; Mezinskis JP; Montgomery MA; Ciraulo DA; Wulsin LR; Barrett JA
    J Addict Dis; 2004; 23(1):77-92. PubMed ID: 15077842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate.
    Díez-Suárez A; Vallejo-Valdivielso M; Marín-Méndez JJ; de Castro-Manglano P; Soutullo CA
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):723-730. PubMed ID: 28817309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P; Maipang P
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.